查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1947960

注射型HIV治疗药物市场（依产品类型、年龄层、最终用户和通路划分），全球预测（2026-2032年）

Injectable HIV Treatment Market by Product Type, Age Group, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，注射用 HIV 药物市场价值将达到 8.1018 亿美元，到 2026 年将成长到 9.1418 亿美元，到 2032 年将达到 19.8423 亿美元，复合年增长率为 13.65%。

关键市场统计数据
基准年 2025 8.1018亿美元
预计年份：2026年 9.1418亿美元
预测年份 2032 1,984,230,000 美元
复合年增长率 (%) 13.65%

本文探讨了注射型长效抗逆转录病毒疗法如何重塑整个治疗生态系统中的依从性、治疗路径和相关人员责任。

注射型长效爱滋病治疗药物正在重新定义爱滋病治疗模式，它将治疗重点从每日用药依从性转移到规律的临床和居家给药，从而提高了治疗的便利性并扩大了医疗服务范围。过去十年，抗逆转录病毒病毒药物化学和给药系统的科学进步，加上患者期望的不断变化、监管机构对探索新型治疗方案的积极态度，以及医疗系统为优先实现持久病毒抑制并减少污名化和治疗负担所做的努力，共同推动了注射剂型从概念验证走向主流临床治疗方案，尤其是在依从性存在挑战的患者群体中。

长效抗逆转录病毒物的进步以及临床、监管和报销实践的演变，正在从根本上改变 HIV 治疗的提供模式。

注射型抗逆转录病毒的出现标誌着爱滋病治疗领域的一个变革性时刻，这得益于分子设计和长效製剂的技术进步，从而延长了给药间隔。这一转变正在改变临床决策，因为临床医生和患者现在除了传统的疗效和安全性终点外，还会考虑长期的药物动力学特征和给药方案。因此，治疗优化越来越关注给药频率、患者意愿以及在门诊、专科中心和家庭医疗保健机构中註射给药的物流。

评估2025年美国关税调整对注射用HIV药物供应韧性、商业合约创新和筹资策略的影响

美国贸易政策和关税的变化可能会影响注射HIV药物的供应链经济、价格谈判和分销策略，尤其是在製造商调整其全球製造地和零件采购的情况下。近期实施的关税调整（将于2025年生效）已经影响了进口原材料、专用给药装置和某些包装组件的成本结构，迫使製造商重新评估其筹资策略和生产计划。为此，一些製造商正在加快关键投入品的在地采购，而另一些製造商则寻求透过其他贸易协定实现关税协调和供应来源多元化。

详细的細項分析揭示了产品属性、给药频率、患者体验、终端用户能力、通路和年龄组如何决定采用路径

细分市场分析揭示了不同产品类型、给药方案、患者体验、最终用户、通路和年龄组在治疗、营运和可及性方面存在差异，这些因素共同影响着药物的采纳路径。例如，卡博特韦、卡博特韦合併利匹韦林、伊斯拉曲韦和来那卡帕韦等产品不仅作用机制和耐受性不同，製剂需求和给药方案也存在差异，这些差异会影响临床定位和服务提供模式。例如，药物动力学持续时间较长的药物需要进行特定的监测和咨询，以应对潜在的抗药性出现和治疗方案的转换。

区域比较分析展示了监管环境、医疗保健基础设施和文化因素将如何影响美洲、欧洲、中东和非洲以及亚太地区的医疗技术采纳。

区域特征影响着美洲、欧洲、中东和非洲以及亚太地区的监管时间表、医疗服务模式和商业策略。每个地区在医疗结构、支付模式和流行病学模式方面都具有独特的特征。在美洲，成熟的临床试验网络、某些市场的一体化支付系统以及积极的倡导团体，共同塑造了加速临床应用、强调治疗效果和准入项目的谈判策略。这种环境促进了製造商、专科诊所和社区组织之间的密切合作，以应对公平性和依从性方面的挑战。

策略产业生态系统概览：揭示製药创新者、服务供应商和合作模式如何携手合作，有效实现注射型爱滋病治疗药物的商业化。

关键产业参与者包括跨国製药公司、专业生物技术创新企业、契约製造组织和利基服务供应商，他们共同构成了支持注射HIV治疗的生态系统。领先的长效抗逆转录病毒和下一代药物研发企业专注于製剂稳定性、药物动力学持久性和安全性，以实现门诊给药。同时，这些公司正投资与契约製造製造商和器械专家建立合作关係，以确保生产的扩充性和与各种器械给药系统的良好相容性。

产业领袖们提出了切实可行的策略建议，旨在协调推广注射型爱滋病疗法、建立稳健的供应链、收集证据并确保公平取得。

行业领导者必须采取多管齐下的策略，以确保永续的临床实践和公平的医疗服务取得。首先，製造商应优先制定整合实施计划，协调供应链准备、临床培训和支付方参与。儘早与医疗服务提供者和专科诊所合作，共同製定给药通讯协定和医护人员培训课程，可以减少实施过程中的阻力，并改善病患疗效。此外，企业还应设计患者援助计划，帮助患者按时就诊，为延长给药间隔提供后勤支持，并就治疗方案转换和潜在副作用提供清晰的咨询。

我们采用了一种透明且严谨的调查方法，该方法整合了二手文献综述、临床医生和支付方访谈、供应链检验以及结果的迭代交叉检验。

本调查方法系统性地结合了二手资料审查、专家访谈和迭代检验，以确保分析的严谨性和对决策者的相关性。二手资料研究涵盖了同行评审的临床文献、监管申报文件、公共卫生指南和产品开发资讯披露，旨在全面了解治疗特征、给药策略和观察到的安全性。临床试验註册资讯和已发表的研究报告提供了特定人群的给药间隔、疗效终点和结局方面的证据，这些证据用于人群细分和操作指导。

总之，我们的研究结果清楚地表明，注射型抗逆转录病毒的临床创新必须与系统性运作一致，才能最大限度地造福患者并实现永续的获取。

长效注射疗法代表着爱滋病治疗领域的一项重要进展，它有望减轻每日服药的负担，减少与口服药物相关的社会歧视，并为不同病患小组提供更多提高用药依从性的途径。为了实现这一目标，研发人员、医疗服务提供者、支付方和社区组织必须通力合作，设计出既能兼顾临床获益又能兼顾实际操作的治疗模式。随着治疗体系的日趋成熟，给药频率、病患病史、最终使用者的能力以及配送物流因素将共同决定针对特定临床情况的合适治疗方法。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依产品类型分類的注射型 HIV 治疗市场

  • 卡博特格拉维尔
  • 卡博特韦+利匹韦林
  • 特拉比尔岛
  • 莉娜·卡帕大厦

9. 依年龄组别分類的注射型 HIV 治疗市场

  • 老年人
  • 成人
  • 儿童

10. 依最终用户分類的注射型爱滋病治疗市场

  • 诊所
  • 家庭医疗保健
  • 医院

11. 按分销管道分類的注射型 HIV 治疗药物市场

  • 在线的
  • 离线

第十二章 注射型爱滋病治疗市场：依地区划分

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

13. 按组别分類的注射型 HIV 治疗市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各国注射型爱滋病治疗市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 美国注射型爱滋病治疗市场

第十六章 中国注射爱滋病治疗市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Accord Healthcare Inc.
  • Amneal Pharmaceuticals, Inc.
  • Aurobindo Pharma Ltd.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Genentech, Inc.
  • Gilead Sciences, Inc.
  • Hetero Labs Limited
  • Johnson & Johnson
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan NV
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Theratechnologies Inc.
  • Viatris Inc.
  • ViiV Healthcare Limited
Product Code: MRR-4F7A6D4FB6AA

The Injectable HIV Treatment Market was valued at USD 810.18 million in 2025 and is projected to grow to USD 914.18 million in 2026, with a CAGR of 13.65%, reaching USD 1,984.23 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 810.18 million
Estimated Year [2026] USD 914.18 million
Forecast Year [2032] USD 1,984.23 million
CAGR (%) 13.65%

Opening perspective on how injectable long-acting antiretroviral therapies are reshaping adherence, care pathways, and stakeholder responsibilities across treatment ecosystems

Injectable long-acting therapies for HIV are redefining treatment paradigms by shifting the focus from daily adherence to periodic clinical and home-based administration, improving convenience and broadening the modalities through which care is delivered. Over the last decade, scientific advances in antiretroviral chemistry and delivery systems have converged with evolving patient expectations, regulatory willingness to consider novel regimens, and health system initiatives that prioritize durable suppression while reducing stigma and treatment burden. Collectively, these forces have moved injectable formulations from experimental proof-of-concept toward mainstream clinical consideration, especially for populations facing adherence challenges.

As these therapies progress through regulatory review and clinical adoption, stakeholders must understand the implications for care models, distribution channels, and workforce training. Clinicians increasingly evaluate long-acting options within the context of integrated care pathways that include adherence counseling, monitoring for injection-site reactions, and coordination with pharmacies and specialty clinics. Payers and policy makers are exploring reimbursement frameworks that reflect administration costs and long-term benefits, while patient advocacy groups emphasize informed choice, access equity, and clear communication about benefits and risks. Consequently, executives and medical leaders require granular insight into product attributes, dosing cadence, patient segments, and end-user workflows to make informed decisions that align clinical outcomes with operational feasibility.

As such, the landscape for injectable HIV treatments now demands strategic alignment across clinical development, regulatory planning, commercialization, and patient support. Transitioning from daily oral regimens to long-acting injectable options will not only affect clinical outcomes but also reshape supply chain logistics, workforce training programs, and the economics of HIV care delivery. This introduction sets the stage for a deeper examination of the transformative shifts, segmentation implications, regulatory and tariff influences, regional dynamics, and the strategic recommendations that follow.

How advances in sustained-release antiretrovirals and evolving clinical, regulatory, and reimbursement practices are fundamentally altering HIV treatment delivery models

The advent of injectable antiretrovirals marks a transformative moment in HIV care, underpinned by technological advances in molecular design and sustained-release formulations that enable extended dosing intervals. This shift alters clinical decision-making, because clinicians and patients now weigh long-term pharmacokinetic profiles and administration schedules alongside traditional efficacy and safety endpoints. As a result, treatment optimization increasingly accounts for dosing frequency, patient preference, and the logistics of delivering injections within outpatient clinics, specialty sites, and home healthcare settings.

Concurrently, emerging evidence and real-world experience have led to evolving regulatory guidance that accommodates novel delivery mechanisms, prompting manufacturers to invest in formulation robustness and post-marketing surveillance. In turn, payers and health systems are piloting reimbursement models that consider bundled administration fees and longer-term adherence benefits, rather than episodic drug dispensing. These developments encourage manufacturers to design comprehensive support programs that encompass clinic training, injection administration certification, and patient adherence services.

Moreover, the pharmaceutical value chain is adapting to handle cold-chain requirements, extended dosing intervals, and alternative distribution networks. Specialty clinics and hospital outpatient departments are revising appointment templates to integrate injection visits, while pharmacies are expanding clinical services to coordinate follow-up and adverse event monitoring. From a patient perspective, the prospect of one-month, two-month, or multi-month dosing windows reduces daily pill burden and associated stigma, thereby influencing care engagement and retention. Taken together, these interconnected shifts require coordinated planning across clinical, commercial, and operational functions to translate long-acting injectable promise into sustainable practice.

Assessment of how 2025 tariff adjustments in the United States have reinforced supply resilience, commercial contracting innovations, and procurement strategies for injectable HIV therapies

Trade policy and tariff changes in the United States can affect supply chain economics, pricing negotiations, and distribution strategies for injectable HIV therapies, particularly as manufacturers coordinate global manufacturing footprints and component sourcing. Recent tariff adjustments introduced in 2025 have influenced cost structures for imported raw materials, specialized delivery devices, and certain packaging components, leading manufacturers to reassess sourcing strategies and production schedules. As manufacturers respond, some have accelerated localization of key inputs, while others have sought tariff harmonization through alternative trade agreements and supplier diversification.

These adjustments have practical implications for procurement teams at hospitals, clinics, and specialty distributors that must manage inventory lead times and maintain continuity of care. In particular, extended-dosing products that require precise scheduling and cold-chain integrity demand predictable supply flows; any disruption can complicate patient appointment adherence and clinical workflows. Consequently, supply chain managers are implementing contingency plans that include secondary suppliers and more conservative inventory buffers to mitigate exposure to tariff-driven lead time variability.

In addition, tariff-driven cost pressures have prompted commercial teams to revise contracting approaches with payers and provider networks. Rather than focusing solely on list pricing, manufacturers are negotiating value-based arrangements and service-inclusive contracts that address administration costs and real-world adherence benefits. These commercial models seek to align incentives across stakeholders while protecting patient access. Overall, the 2025 tariff environment has reinforced the need for nimble supply strategies, strengthened manufacturer-provider collaboration, and proactive engagement with procurement and reimbursement stakeholders to safeguard uninterrupted patient care.

Deep-dive segmentation analysis revealing how product attributes, dosing cadences, patient experience, end-user capacity, distribution channels, and age cohorts determine adoption pathways

Segmentation analysis reveals distinct therapeutic, operational, and access implications across the product types, dosing schedules, patient experiences, end users, distribution channels, and age cohorts that shape adoption pathways. Products such as cabotegravir, cabotegravir combined with rilpivirine, islatravir, and lenacapavir differ not only in mechanism of action and tolerability profiles but also in formulation requirements and administration considerations, which in turn influence clinical positioning and service delivery models. For instance, agents with longer pharmacokinetic tails necessitate specific monitoring and counseling to manage potential resistance emergence and treatment transitions.

Dosing frequency is a pivotal variable, with one-month regimens presenting different adherence and scheduling trade-offs compared with two-month intervals and three months or more options, the latter of which includes three-month and six-month alternatives. Extended-interval dosing reduces appointment frequency and may improve persistence for some patients, but it also places a premium on ensuring appointment attendance and planned follow-up to capture rare adverse events. Therefore, operational workflows vary materially depending on cadence, influencing staffing models, clinic throughput, and home-care coordination.

Patient experience segmentation between treatment-experienced and treatment-naive individuals affects clinical decision trees, as prior exposure to antiretrovirals, resistance profiles, and patient expectations inform regimen choice. End users-comprising clinics, home healthcare services, and hospitals-each present different infrastructure and staffing capabilities for administering injections and monitoring outcomes. Distribution channel distinctions across hospitals, retail pharmacies, and specialty clinics dictate storage, dispensing responsibilities, and coordination efforts; some channels may offer integrated clinical services while others focus on logistics and counseling.

Age group considerations for adolescents, adults, and pediatric populations introduce unique clinical and psychosocial dimensions, including dosing adjustments, caregiver involvement, and consent processes. Collectively, these segmentation dimensions interact in complex ways that determine which formulations and delivery models are appropriate for specific patient cohorts and care settings. As a result, developers and health systems must craft tailored rollout strategies that reflect the interplay of product properties, dosing frequency, patient history, care setting, distribution mechanics, and age-specific needs.

Comparative regional landscape analysis illustrating how regulatory environments, healthcare infrastructure, and cultural dynamics shape adoption across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics influence regulatory timelines, care delivery models, and commercial strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific, each of which presents distinct healthcare structures, payer models, and epidemiological patterns. In the Americas, mature clinical trial networks, consolidated payer systems in certain markets, and active advocacy groups shape rapid clinical adoption and negotiation approaches that emphasize outcomes and access programs. This environment fosters close collaboration between manufacturers, specialty clinics, and community organizations to address equity and adherence challenges.

Europe, Middle East & Africa encompasses a broad spectrum of health systems, where regulatory harmonization efforts, national reimbursement assessments, and infrastructure variability affect deployment speed and service design. In some high-resource European markets, centralized HTA and pricing review processes require robust real-world evidence and pharmacoeconomic substantiation, whereas in parts of the Middle East and Africa, infrastructure constraints and differing burden of disease necessitate tailored distribution strategies and capacity-building initiatives. Manufacturers often partner with local stakeholders to implement training programs and to adapt supply chains to regional realities.

In the Asia-Pacific region, diverse payer arrangements and growing clinical research capacity coexist with rapidly evolving public health priorities. Several markets in the region place strong emphasis on cost-effectiveness and scalable service delivery, prompting manufacturers to consider tiered access models, localized manufacturing partnerships, and targeted pilot programs in urban centers before broader rollout. Across all regions, cultural factors and stigma considerations influence patient acceptance and adherence, underscoring the importance of community engagement, culturally competent education materials, and flexible service delivery options that can include clinic-based and home healthcare settings.

Strategic industry ecosystem overview that highlights how pharmaceutical innovators, service providers, and collaboration models are aligning to commercialize injectable HIV therapies effectively

Key industry participants encompass multinational pharmaceutical companies, specialized biotech innovators, contract manufacturing organizations, and niche service providers that together form an ecosystem supporting injectable HIV therapies. Leading developers of long-acting antiretrovirals and next-generation agents are focusing on formulation stability, pharmacokinetic longevity, and safety profiles that facilitate outpatient administration. These companies are simultaneously investing in partnerships with contract manufacturers and device specialists to ensure scalable production and robust device-delivery compatibility.

In parallel, specialty clinics, hospital outpatient departments, and home healthcare providers are emerging as critical collaborators in execution, often entering into value-chain partnerships that coordinate administration, monitoring, and adherence support programs. Clinical research organizations and academic networks continue to supply evidence through pragmatic trials and post-marketing observational studies, while payers and health technology assessment bodies evaluate real-world outcomes to inform coverage policies. Additionally, smaller biotech firms play an outsized role by innovating novel mechanisms of action and delivery platforms that complement established therapies, creating licensing and collaboration opportunities for larger firms seeking diversified portfolios.

Across the ecosystem, strategic alliances and commercial models are evolving to reflect shared-risk arrangements and service-inclusive contracting. Companies are prioritizing integrated solutions that bundle drug supply with administration training, patient support, and data collection to demonstrate value. The competitive landscape therefore balances therapeutic differentiation with operational capability, and success often depends on the ability to execute seamless coordination between R&D, manufacturing, clinical operations, and commercial functions.

Actionable strategic recommendations for industry leaders to ensure coordinated launches, resilient supply chains, evidence generation, and equitable access for injectable HIV therapies

Industry leaders must adopt multifaceted strategies to translate long-acting injectable innovations into sustainable clinical practice and equitable access. First, manufacturers should prioritize integrated launch planning that synchronizes supply chain readiness, clinical training, and payer engagement. Early collaboration with providers and specialty clinics to co-develop administration protocols and workforce training curricula will reduce rollout friction and improve patient outcomes. Furthermore, companies should design patient support programs that address appointment adherence, logistics for extended-dosing windows, and clear counseling on treatment transitions and potential adverse effects.

Second, commercial teams ought to craft contracting approaches that align incentives across stakeholders. Value-based and service-inclusive contracts can help reconcile higher per-dose costs with reduced visit frequency and improved persistence. Negotiations should emphasize measurable clinical endpoints and operational metrics to support reimbursement discussions. Third, manufacturers and providers should invest in data generation initiatives focused on real-world effectiveness, safety monitoring, and health economics; these data streams will strengthen payer discussions and inform iterative improvements to care pathways.

Fourth, supply chain resilience must be a priority, with diversified sourcing, localized manufacturing where feasible, and contingency inventory strategies to mitigate tariff and logistics disruptions. Fifth, companies should pursue targeted access strategies that reflect regional infrastructure and patient population needs, including partnerships with community organizations to address stigma and facilitate retention. Finally, technology-enabled solutions such as appointment reminders, telehealth follow-ups, and electronic registries will support long-term adherence and provide analytics that guide continuous improvement. Collectively, these actions will position industry leaders to navigate the clinical, operational, and commercial complexities of injectable HIV treatment adoption.

Transparent and rigorous research methodology integrating secondary literature review, clinician and payer interviews, supply chain validation, and iterative cross-validation of findings

The research methodology relied on a structured combination of secondary evidence review, primary expert engagement, and iterative validation to ensure analytical rigor and relevance to decision-makers. Secondary research encompassed peer-reviewed clinical literature, regulatory filings, public health guidance, and product development disclosures to compile a comprehensive view of therapeutic attributes, dosing strategies, and observed safety profiles. Clinical trial registries and published study reports provided evidence on dosing intervals, efficacy endpoints, and population-specific outcomes that informed segmentation and operational implications.

Primary research included in-depth interviews with clinicians, pharmacists, supply chain managers, payer representatives, and patient advocacy stakeholders to capture practical insights on administration workflows, reimbursement considerations, and patient preferences. These interviews were designed to surface real-world challenges and successful implementation practices that often do not appear in published studies. In addition, dialogues with manufacturing and distribution experts clarified requirements for cold-chain logistics, device compatibility, and contingency planning in the face of trade-policy changes.

Analytical approaches integrated qualitative thematic analysis with comparative assessment frameworks that mapped product characteristics to care settings, dosing cadences, and patient segments. Findings were cross-validated through triangulation between secondary sources and primary interview inputs, with attention to regional variability and regulatory differences. Finally, an editorial review process ensured that conclusions were supported by cited evidence and expert input, and that recommendations were actionable for commercial, clinical, and policy stakeholders.

Concluding synthesis articulating how clinical innovation in injectable antiretrovirals must be matched by system-wide execution to maximize patient benefit and sustainable access

Injectable long-acting therapies constitute a pivotal evolution in HIV treatment that offers the potential to alleviate daily pill burden, reduce stigma associated with oral dosing, and provide alternative adherence pathways for diverse patient groups. Realizing this potential requires coordinated effort across developers, providers, payers, and community organizations to design care models that reconcile clinical benefits with operational realities. As the therapeutic landscape matures, attention to dosing cadence, patient history, end-user capabilities, and distribution logistics will determine which regimens fit specific clinical contexts.

Moreover, external factors such as trade policy adjustments, regional regulatory nuances, and infrastructure variability will continue to shape deployment timelines and commercial strategies. Consequently, stakeholders that invest early in supply chain resilience, data generation, and collaborative contracting are better positioned to sustain patient access and demonstrate value. Ultimately, the shift toward injectables is not simply a clinical development story but a systems challenge that intersects clinical practice, health economics, and patient-centered care design. Stakeholders who integrate cross-functional planning with evidence-based implementation stand to improve outcomes and expand access for people living with HIV.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Injectable HIV Treatment Market, by Product Type

  • 8.1. Cabotegravir
  • 8.2. Cabotegravir Plus Rilpivirine
  • 8.3. Islatravir
  • 8.4. Lenacapavir

9. Injectable HIV Treatment Market, by Age Group

  • 9.1. Geriatrics
  • 9.2. Adults
  • 9.3. Pediatrics

10. Injectable HIV Treatment Market, by End User

  • 10.1. Clinics
  • 10.2. Home Healthcare
  • 10.3. Hospitals

11. Injectable HIV Treatment Market, by Distribution Channel

  • 11.1. Online
  • 11.2. Offline

12. Injectable HIV Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Injectable HIV Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Injectable HIV Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Injectable HIV Treatment Market

16. China Injectable HIV Treatment Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Accord Healthcare Inc.
  • 17.7. Amneal Pharmaceuticals, Inc.
  • 17.8. Aurobindo Pharma Ltd.
  • 17.9. Boehringer Ingelheim International GmbH
  • 17.10. Bristol Myers Squibb Company
  • 17.11. Cipla Ltd.
  • 17.12. Dr. Reddy's Laboratories Ltd.
  • 17.13. Genentech, Inc.
  • 17.14. Gilead Sciences, Inc.
  • 17.15. Hetero Labs Limited
  • 17.16. Johnson & Johnson
  • 17.17. Lupin Limited
  • 17.18. Merck & Co., Inc.
  • 17.19. Mylan N.V.
  • 17.20. Sun Pharmaceutical Industries Ltd.
  • 17.21. Teva Pharmaceutical Industries Ltd.
  • 17.22. Theratechnologies Inc.
  • 17.23. Viatris Inc.
  • 17.24. ViiV Healthcare Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INJECTABLE HIV TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL INJECTABLE HIV TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES INJECTABLE HIV TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA INJECTABLE HIV TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY CABOTEGRAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY CABOTEGRAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY CABOTEGRAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY CABOTEGRAVIR PLUS RILPIVIRINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY CABOTEGRAVIR PLUS RILPIVIRINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY CABOTEGRAVIR PLUS RILPIVIRINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY ISLATRAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY ISLATRAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY ISLATRAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY LENACAPAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY LENACAPAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY LENACAPAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY GERIATRICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY GERIATRICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY GERIATRICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. AMERICAS INJECTABLE HIV TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 44. AMERICAS INJECTABLE HIV TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 45. AMERICAS INJECTABLE HIV TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. AMERICAS INJECTABLE HIV TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS INJECTABLE HIV TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 48. NORTH AMERICA INJECTABLE HIV TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. NORTH AMERICA INJECTABLE HIV TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 50. NORTH AMERICA INJECTABLE HIV TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. NORTH AMERICA INJECTABLE HIV TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 52. NORTH AMERICA INJECTABLE HIV TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 53. LATIN AMERICA INJECTABLE HIV TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. LATIN AMERICA INJECTABLE HIV TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. LATIN AMERICA INJECTABLE HIV TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. LATIN AMERICA INJECTABLE HIV TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 57. LATIN AMERICA INJECTABLE HIV TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA INJECTABLE HIV TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA INJECTABLE HIV TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA INJECTABLE HIV TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA INJECTABLE HIV TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA INJECTABLE HIV TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE INJECTABLE HIV TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE INJECTABLE HIV TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE INJECTABLE HIV TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE INJECTABLE HIV TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE INJECTABLE HIV TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 68. MIDDLE EAST INJECTABLE HIV TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. MIDDLE EAST INJECTABLE HIV TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. MIDDLE EAST INJECTABLE HIV TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. MIDDLE EAST INJECTABLE HIV TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. MIDDLE EAST INJECTABLE HIV TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. AFRICA INJECTABLE HIV TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. AFRICA INJECTABLE HIV TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. AFRICA INJECTABLE HIV TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. AFRICA INJECTABLE HIV TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. AFRICA INJECTABLE HIV TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC INJECTABLE HIV TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC INJECTABLE HIV TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC INJECTABLE HIV TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC INJECTABLE HIV TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC INJECTABLE HIV TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. ASEAN INJECTABLE HIV TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. ASEAN INJECTABLE HIV TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. ASEAN INJECTABLE HIV TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. ASEAN INJECTABLE HIV TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. ASEAN INJECTABLE HIV TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. GCC INJECTABLE HIV TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GCC INJECTABLE HIV TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. GCC INJECTABLE HIV TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GCC INJECTABLE HIV TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. GCC INJECTABLE HIV TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPEAN UNION INJECTABLE HIV TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPEAN UNION INJECTABLE HIV TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPEAN UNION INJECTABLE HIV TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPEAN UNION INJECTABLE HIV TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPEAN UNION INJECTABLE HIV TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. BRICS INJECTABLE HIV TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. BRICS INJECTABLE HIV TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. BRICS INJECTABLE HIV TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. BRICS INJECTABLE HIV TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. BRICS INJECTABLE HIV TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. G7 INJECTABLE HIV TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. G7 INJECTABLE HIV TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. G7 INJECTABLE HIV TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. G7 INJECTABLE HIV TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. G7 INJECTABLE HIV TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. NATO INJECTABLE HIV TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. NATO INJECTABLE HIV TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. NATO INJECTABLE HIV TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. NATO INJECTABLE HIV TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. NATO INJECTABLE HIV TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. UNITED STATES INJECTABLE HIV TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 116. UNITED STATES INJECTABLE HIV TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. UNITED STATES INJECTABLE HIV TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. UNITED STATES INJECTABLE HIV TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. UNITED STATES INJECTABLE HIV TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. CHINA INJECTABLE HIV TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 121. CHINA INJECTABLE HIV TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. CHINA INJECTABLE HIV TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. CHINA INJECTABLE HIV TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. CHINA INJECTABLE HIV TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)